These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease. Ponnayyan Sulochana S; Sharma K; Mullangi R; Sukumaran SK Biomed Chromatogr; 2014 Nov; 28(11):1431-90. PubMed ID: 24515838 [TBL] [Abstract][Full Text] [Related]
26. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic. Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371 [TBL] [Abstract][Full Text] [Related]
27. [Current strategies of pathogenetic therapy of Alzheimer's disease]. Gavrilova SI; Zharikov GA Vestn Ross Akad Med Nauk; 2001; (7):13-8. PubMed ID: 11523421 [TBL] [Abstract][Full Text] [Related]
29. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. Seltzer B J Int Med Res; 2006; 34(4):339-47. PubMed ID: 16989488 [TBL] [Abstract][Full Text] [Related]
30. Realistic expectations for treatment success in Alzheimer's disease. Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215 [TBL] [Abstract][Full Text] [Related]
32. Alzheimer Disease: Monotherapy vs. Combination Therapy. Lawler E; Avila A Am Fam Physician; 2017 Apr; 95(7):452. PubMed ID: 28409590 [No Abstract] [Full Text] [Related]
33. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502 [TBL] [Abstract][Full Text] [Related]
34. Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease. Formiga F; Fort I; Robles MJ; Rodriguez D; Regalado P Dement Geriatr Cogn Disord; 2010; 29(3):198-203. PubMed ID: 20332637 [TBL] [Abstract][Full Text] [Related]
35. New drugs for Alzheimer's disease in Japan. Takeda M; Tanaka T; Okochi M Psychiatry Clin Neurosci; 2011 Aug; 65(5):399-404. PubMed ID: 21851448 [No Abstract] [Full Text] [Related]
36. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Aisen PS; Cummings J; Schneider LS Cold Spring Harb Perspect Med; 2012 Mar; 2(3):a006395. PubMed ID: 22393531 [TBL] [Abstract][Full Text] [Related]
37. [Cholinesterase inhibitor therapy in long term care settings]. Vantelon C; Gilbert S; Kerneis S; Wolmark Y; Legrain S; Kergoat MJ Rev Med Interne; 2006 Aug; 27(8):588-94. PubMed ID: 16806591 [TBL] [Abstract][Full Text] [Related]
38. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032 [TBL] [Abstract][Full Text] [Related]
40. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]